Clinical trial Recruiting at 1 site Interventional Ages 20 to 70

Effects of Cetoleic Acid on Atherosclerosis

Official title: Effects of Ketolic Acid on Atherosclerosis Markers in High-risk Patients With Metabolic Syndrome (Effekt av Ketolinsyre på aterosklerosemarkører i høyrisikopasienter Med Metabolsk Syndrom)

Run by Oslo University Hospital · NCT06172335 · Data updated 2026-11-12

This study is testing if taking cetoleic acid-rich oil can help improve heart health and lower risks for people with metabolic syndrome.

Quick facts

Study typeInterventional
Ages20 Years to 70 Years
SexAll
Enrollment70 (estimated)
SponsorOslo University Hospital
Academic / other
Locations1 site (Oslo)
StatusRecruiting
StartedJanuary 3, 2024
Main results expectedDecember 30, 2024
Study endsDecember 31, 2027
Registry record updatedJanuary 16, 2025
Trial IDNCT06172335 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men and women aged 20-70 with triglycerides greater than 1.7 mmol/L and specific waist measurements indicating metabolic syndrome.

Probably not a fit

Patients with chronic diseases, ongoing cancer treatment, or those with high cholesterol levels will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of cetoleic acid-rich oil on atherosclerosis in individuals with metabolic syndrome. Participants will be randomly assigned to receive either the cetoleic acid oil or a control oil with lower cetoleic acid but similar levels of EPA and DHA. The study will measure changes in plasma levels of EPA and DHA, as well as various atherosclerotic markers, glucose, c-peptide, and triglycerides over a four-week period. The trial aims to determine if cetoleic acid can improve metabolic health and cardiovascular risk factors.

Why it matters

Potential benefit: If successful, this study could lead to improved dietary interventions for preventing cardiovascular diseases in individuals with metabolic syndrome.

How similar studies have gone: Previous studies have shown promising results with omega-3 fatty acids in cardiovascular health, suggesting potential success for this novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Triglycerides \> 1.7 mmol/L
* Waist measurement \> 80 cm (women) and \> 94 cm (men)

Exclusion Criteria:

* Chronic disease (liver/kidney/metabolism)
* Ongoing active cancer treatment
* Excessive alcohol consumption (\>40g/day)
* Pregnant/breastfeeding or planned pregnancy during the intervention
* High intake of fish (\>3 weekly meals)
* Level of free thyroxine (T4) and triiodothyronine (T3) outside reference ranges.
* Hypertension (≥ 160/ 100 mmHg)
* Total cholesterol \> 7.8 mmol/L
* Blood donation during the intervention period
* Difficulty following the protocol
* Smoking or sniffing
* Regular use (\> 1 day/week) of anti-inflammatory drugs
* Regular use of omega-3 supplements/cod liver oil
* Drug use other than stable use of statins, hypertension drugs (Ca antagonists, diuretics and beta blockers).
* Hormonal treatment excluding stable use of thyroxine and birth control pills/contraceptive rod

Where it's running

  • Oslo University Hospital
    Oslo, Norway
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.